TransMedics Group Inc. (TMDX)
TransMedics: Why I'm Still Bullish After The Collapse
TransMedics (TMDX) faces decelerating revenue growth, margin pressure, and increased investment, yet maintains strong market share gains and competitive positioning. TMDX's logistics and clinical services now comprise nearly 40% of revenue, enhancing competitive advantages and supporting long-term margin strength. Despite growth normalizing to 20-25% and compressed margins, I see current valuation at 4x EV/Sales as attractive, supporting a Buy rating.
TransMedics (TMDX) Down 4.4% Since Last Earnings Report: Can It Rebound?
TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock?
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TMDX is advancing its OCS platform and transplant ecosystem, but margin pressure from expansion investments remains a key concern.
TransMedics: Despite Earnings Miss, Growth Story Remains Intact
TransMedics remains a 'Strong Buy' despite a 50% stock decline and Q1 2026 earnings miss, supported by robust long-term growth initiatives. TMDX's portfolio expansion includes CHOPS as a complementary offering and aggressive European NOP rollout, aiming to expand its addressable market. Q1 2026 revenue grew 21% year-over-year to $174 million, led by liver segment strength, though higher costs compressed margins and net income.
TransMedics: Cheaper, But Still Priced For Perfection
TransMedics Group, Inc. remains a Sell as its valuation still bakes in near-perfect execution, despite the stock being nearly 40% cheaper since October. TMDX's valuation implies sustaining some combination of between 9–20% revenue growth and 9–17% free cash flow margins, which remains a high bar given current trends. Growth levers like CHOPS, international expansion, and potential OPO conversion are either hedges, slow-moving, or highly uncertain, making current valuation hard to justify.
TMDX Dips After Posting Q1 Earnings & Revenue Miss, Margins Fall
TransMedics' Q1 revenues rise 21% on strong OCS demand, but a sharp EPS miss and margin pressure send shares down despite continued logistics growth.
TransMedics Group, Inc. (TMDX) Q1 2026 Earnings Call Transcript
TransMedics Group, Inc. (TMDX) Q1 2026 Earnings Call Transcript
TransMedics (TMDX) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for TransMedics (TMDX) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
TransMedics (TMDX) Q1 Earnings and Revenues Miss Estimates
TransMedics (TMDX) came out with quarterly earnings of $0.3 per share, missing the Zacks Consensus Estimate of $0.62 per share. This compares to earnings of $0.7 per share a year ago.
TransMedics: Revolutionizing The Organ Transplant Market While Trading At A Discount
TransMedics Group is a strong buy, leveraging its technological and logistical moat in organ transport, with OCS and NOP programs driving sector outperformance. TMDX trades at a 39x Non-GAAP PE and 5.2x NTM EV/Sales, appearing undervalued relative to its 20%-25% growth guidance and MedTech peers. Key growth catalysts include the OCS Kidney launch (late 2026/early 2027) and European expansion, particularly in Italy, positioning TMDX for significant volume upside.
TransMedics (TMDX) Down 20.3% Since Last Earnings Report: Can It Rebound?
TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock?
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TMDX rides OCS adoption and strong fourth-quarter results, but margin pressure raises questions for investors.
